Side Effects After Direct-acting Antiviral Treatment

Direct Acting Agents in Hepatitis C Patients

NCT03145844 ·Status: COMPLETED

"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt

NCT03510637 ·Status: UNKNOWN

Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

NCT00807001 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002 ·Status: UNKNOWN

Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients

NCT02057003 ·Status: UNKNOWN

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

NCT00445315 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C

NCT02639585 ·Status: UNKNOWN ·Phase: PHASE4

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

NCT01842451 ·Status: COMPLETED ·Phase: PHASE2

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

NCT01508130 ·Status: COMPLETED

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

NCT03163849 ·Status: UNKNOWN ·Phase: PHASE3

Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

NCT02531269 ·Status: COMPLETED

Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)

NCT00724451 ·Status: COMPLETED

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

NCT04952207 ·Status: UNKNOWN

Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

NCT03342261 ·Status: COMPLETED

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

NCT02349048 ·Status: COMPLETED ·Phase: PHASE2

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

NCT01168856 ·Status: TERMINATED

Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity

NCT04729153 ·Status: UNKNOWN

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

NCT01185860 ·Status: COMPLETED ·Phase: PHASE1

Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients

NCT03244371 ·Status: UNKNOWN ·Phase: NA

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)

NCT01743521 ·Status: COMPLETED ·Phase: PHASE4

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

NCT02496078 ·Status: COMPLETED ·Phase: PHASE3

Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection

NCT03603327 ·Status: COMPLETED ·Phase: NA

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

NCT03887637 ·Status: UNKNOWN

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

NCT01797848 ·Status: WITHDRAWN ·Phase: PHASE3

Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse

NCT04662138 ·Status: UNKNOWN